Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes
Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. Lenalidomide Performance in the Real World: Patterns of Utilization and Effectiveness in a Medicare Population with Myelodysplastic Syndromes. Blood 2012, 120: 3837. DOI: 10.1182/blood.v120.21.3837.3837.Peer-Reviewed Original ResearchErythropoiesis-stimulating agentsTransfusion independenceTransfusion useMyelodysplastic syndromeRisk groupsTransfusion statusLens useObservational studyClaims dataLarge population-based observational studiesResponse rateIntermediate-risk myelodysplastic syndromesPopulation-based observational studyICD-9-CM codesCycles of therapyInitiation of lenalidomidePoor performance statusReceipt of transfusionClinical trial evidenceInitiation of treatmentAge 75 yearsTransfusion-dependent anemiaEnd of studyZIP Code-level measuresMedicare Part AUtilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D.
Zeidan A, Baer M, Gore S, Sasane M, Paley C, McNally D, Davidoff A. Utilization Patterns of Iron Chelation Therapy in Transfusion-Dependent Myelodysplastic Syndrome Patients Enrolled in Medicare Part D. Blood 2012, 120: 3178. DOI: 10.1182/blood.v120.21.3178.3178.Peer-Reviewed Original ResearchIron chelation therapyCongestive heart failureStudy cohortCardiac conduction disordersMedicare Part DTransfusion thresholdPerformance statusRed blood cellsMyelodysplastic syndromeRenal diseaseConduction disordersChelation therapyObservation periodHistory of CHFPart DCox proportional hazards modelICD-9-CM codesErythropoiesis-stimulating agentsCoronary artery diseaseEntire study cohortMyelodysplastic syndrome patientsEnd of studyProportional hazards modelUtilization patternsMedicare enrollment filesDeferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes
Zeidan A, Hendrick F, Friedmann E, Gore S, Baer M, Sasane M, Paley C, McNally D, Davidoff A. Deferasirox Is Associated with Reduced Mortality Risk in a Medicare Population with Myelodysplastic Syndromes. Blood 2012, 120: 426. DOI: 10.1182/blood.v120.21.426.426.Peer-Reviewed Original ResearchIron chelation therapyErythropoiesis-stimulating agentsMarginal structural modelsRisk of deathMyelodysplastic syndromeRenal diseaseTransfusion thresholdThyroid diseaseIron overloadChelation therapyObservation periodHealth statusOral iron chelation therapyICD-9-CM diagnosisICD-9-CM codesOlder MDS patientsSolid tumor diagnosisDuration of therapyCo-morbid conditionsOnset of diabetesEnd of studyOverall survival analysisPatients' health statusReduced mortality riskDrug side effects